moderna goldman sachs

Moderna, Goldman Sachs

Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Seeking Alpha on MSN · 3d

Moderna slips as Goldman Sachs downgrades on revenue outlook

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Read more here.

Fintel on MSN · 3d

Goldman Sachs Downgrades Moderna (MRNA)

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to Neutral. Analyst Price Forecast Suggests 57.38% Upside As of January 28, 2025, the average one-year price target for Moderna is $70.

Morningstar3d

Moderna's stock is falling. Goldman Sachs says it's no longer a buy.

Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech's second cut to product revenue guidance in six months. Moderna shares (MRNA) fell 2% ...

3don MSN

Why Moderna (MRNA) Crashed on Wednesday?

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Moderna (MRNA) Receives a Hold from Bernstein

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Moderna Stock Is Sliding Wednesday: Here's Why

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results